Activity Information

The ACR Convergence Replay includes six popular video lectures from scientific sessions at ACR Convergence 2024, plus a Q&A session for each. The lectures encompass a variety of topics, including systemic sclerosis, rheumatoid arthritis-related interstitial lung disease, juvenile dermatomyositis, and the use of AI documentation in rheumatology.

The activity includes the following sessions:

• Optimizing the Management of Skin Disease in Systemic Sclerosis: Using Clinical Features and Novel Disease Activity Measures to Guide Treatment Decisions
• Are We Putting the CAR-T Before the Horse?
• Rheumatoid Arthritis-Associated Interstitial Lung Disease: Advances in Screening, Diagnosis and Patient Phenotyping
• AI: The Next Breakthrough in Documentation for Rheumatology
• Anti-MDA5 Juvenile Dermatomyositis: Clinical Presentation and Treatment
• Year in Review
  
  

Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.

ACR/ARP Member: $299
ACR/ARP Potential Member: $399

Target Audience

Rheumatologists, internists, primary care providers, physician assistants, residents, fellows in training, advanced practice nurses, students, rheumatology interprofessionals who care for patients with rheumatic diseases, and those interested or engaged in rheumatology research.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Analyze and explain recent scientific and clinical advancements in understanding the pathogenesis of rheumatic diseases
• Evaluate and demonstrate proficiency in diagnosing and managing a range of rheumatic diseases and conditions
• Apply evidence-based strategies to effectively manage emerging challenges in rheumatic conditions

CME

Accreditation Statement

The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Designation Statement

The American College of Rheumatology designates this Enduring Material for a maximum of 8.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants can claim up to 1.25 AMA PRA Category 1 Credit(s)™ for completing the pre-and post-assessments, and up to 7.25 AMA PRA Category 1 Credit(s)™ for attending the ACR Convergence Replay 2024.

CME credit must be claimed by April 3, 2028, at 11:59 PM ET.

Financial Relationship Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships

All individuals that participate in this activity and were able to change or influence the content of the activity have disclosed to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:

1. Advisor or review panel member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/research support
6. Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
7. Independent contractor
8. Executive role and/or ownership interest
9. Royalties and/or patent beneficiary
10. Intellectual property/patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Private investigator
13. Expert witness
14. Equity interest
15. Other: specify details

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. ACR Convergence Replay 2024 Financial Relationship Disclosures

Acknowledgment of Commercial Support 

No commercial support was provided for this activity.

Educational Activity Policies

See ACR educational activity policies, including the online enduring activity refund policy.